成人免疫性血小板减少症患者的骨折风险与双膦酸盐使用:一项全国性人群研究
这项全国性登记队列研究纳入4030例原发性免疫性血小板减少症(pITP)患者、550例继发性免疫性血小板减少症(sITP)患者和182939名年龄性别匹配的普通人群对照,随访新发骨折。pITP患者任何骨折的校正病因特异性风险比为1.37(95%CI 1.23;1.54),sITP为1.54(95%CI 1.17;2.03);第一年pITP为1.82(95%CI 1.39;2.40),sITP为2.78(95%CI 1.58;4.91)。ITP患者双膦酸盐使用率高于普通人群。
要点
- pITP患者任何骨折校正csHR为1.37(95%CI 1.23;1.54),sITP为1.54(95%CI 1.17;2.03)。
- 第一年骨折风险更高:pITP csHR 1.82(95%CI 1.39;2.40),sITP csHR 2.78(95%CI 1.58;4.91)。
- ITP患者双膦酸盐使用率在日历年和诊断后早期均高于普通人群。
核心结论
- 与普通人群相比,ITP患者的骨折风险和双膦酸盐使用均更高。
研究设计与样本
- 全国性登记队列研究,纳入4030例pITP患者(中位年龄60岁,IQR 40-74)、550例sITP患者(中位年龄59岁,IQR 43-74)和182939名年龄性别匹配的普通人群对照,随访新发骨折。
主要发现
- 任何骨折的校正病因特异性风险比:pITP为1.37(95%CI 1.23;1.54),sITP为1.54(95%CI 1.17;2.03)。
- 第一年骨折校正病因特异性风险比:pITP为1.82(95%CI 1.39;2.40),sITP为2.78(95%CI 1.58;4.91)。
- ITP患者双膦酸盐使用在日历年和诊断后早期均高于普通人群。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Corticosteroids remain the first-line treatment of immune thrombocytopenia (ITP), but increase the risk of osteoporosis and fractures. Bisphosphonates are used for the treatment of osteoporosis, but their usage among patients with ITP has not been systemically described. We investigated the risk of fractures and the use of bisphosphonates in adult patients with primary (pITP) and secondary ITP (sITP) compared with matched comparators in a nationwide registry-based cohort study. We identified 4030 patients with pITP (median age 60 years [IQR, 40-74]), 550 with sITP (median age 59 years [IQR, 43-74]) and 182 939 age-sex-matched general population comparators. All individuals were followed for incident fractures. Bisphosphonate use was estimated for calendar-years and in temporal relation to the ITP diagnosis. Adjusted cause-specific hazard ratio (csHR) for any fracture was 1.37 (95% confidence interval [CI] 1.23; 1.54) for pITP and 1.54 (1.17; 2.03) for sITP. The first-year csHR was 1.82 (1.39; 2.40) for pITP and 2.78 (1.58; 4.91) for sITP. Bisphosphonate use over calendar-years and in the early years following ITP diagnosis was higher among patients with ITP diagnosis compared with the general population. In conclusion, the risk of fractures and the use of bisphosphonates are higher in patients with ITP compared with the general population.
引用
- Mannering N, Hansen DL, Moulis G, et al. Risk of fractures and use of bisphosphonates in adult patients with immune thrombocytopenia-A nationwide population-based study. Br J Haematol. 2024. PMID: 38302094. doi:10.1111/bjh.19301
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。